ML-004 for Autism Spectrum Disorder

Autism social communication endpoints have historically been very difficult, with high placebo response and prior failures (e.g., balovaptan, bumetanide). ML-004 is a 5-HT1B/1D agonist with limited prior efficacy signal in ASD core symptoms. Trial is reasonably sized (n=161) and well-controlled, but ABI-SC is a novel scale and core social deficits rarely move in Phase 2. Base rate for Phase 2 CNS/ASD positive primary ~30-35%. Topline expected mid-Aug 2026.”},

Phase 2 ASD behavioral endpoint in adolescents/adults is subjective and vulnerable to placebo and heterogeneity. Completed status reduces execution risk, but no prior efficacy data are provided and ABI social communication change is a challenging signal to show convincingly.

Phase 2 autism trial with novel oral ML-004; primary endpoint ABI social communication change; completed status with no positive efficacy signals or prior data in summary; autism endpoints prone to high placebo effects and modest Phase 2 hit rates.

ML-004, a 5-HT1B agonist, is tested in a 161-patient Phase 2 trial for ASD social communication deficits, with results expected in mid-August 2026. Historically, ASD trials targeting core social symptoms face high failure rates due to significant placebo responses on subjective caregiver-reported scales like the ABI. Given the lack of prior efficacy data, the probability of success is low.

Phase 2 autism trials have a low historical success rate (~20%). No prior efficacy data or mechanism details are provided. Completed status does not change pre-existing probability without disclosed results.

Phase 2 ASD trials for social communication have a very high historical failure rate due to high placebo response and patient heterogeneity. ABI is a subjective, caregiver-rated endpoint prone to placebo effects. ML-004 lacks prior pivotal proof-of-concept.

Phase 2 ASD trials have high failure rates due to heterogeneous populations and placebo effects. ML-004 targets social communication, a notoriously difficult endpoint. With the trial completed in March 2026 and no positive press release issued by May, negative results are highly likely. Lack of announcement typically signals failure in biotech.

Phase 2 autism trial of oral ML‑004 has limited prior data, a broad 12‑45 age range, and a single social‑communication endpoint that historically shows modest drug effects. No earlier efficacy signals reported, and autism trials often fail in Phase 2, suggesting a low chance of a statistically positive ABI‑Social Communication change.

Phase 2 ASD trials have historically high failure rates. ML-004 targets social communication via novel mechanism; no prior Phase 2 data disclosed. Primary endpoint ABI-Social Communication is a newer scale with limited regulatory precedent. Trial completed 78 days ago with no top-line release, suggesting negative or marginal results (positive trials typically disclosed promptly). Small biotech disclosure risk cuts both ways but delay favors negative interpretation.

Phase 2 ASD trials historically face low success rates. Social communication is a difficult target, with most compounds failing to show meaningful improvement on standardized measures. No disclosed interim results or positive signals available for this specific trial. The therapeutic area's track record suggests intrinsic odds below market's implied 35% probability.